These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32959246)

  • 21. Improving protein glycan coupling technology (PGCT) for glycoconjugate vaccine production.
    Dow JM; Mauri M; Scott TA; Wren BW
    Expert Rev Vaccines; 2020 Jun; 19(6):507-527. PubMed ID: 32627609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morphological characterization of a plant-made virus-like particle vaccine bearing influenza virus hemagglutinins by electron microscopy.
    Lindsay BJ; Bonar MM; Costas-Cancelas IN; Hunt K; Makarkov AI; Chierzi S; Krawczyk CM; Landry N; Ward BJ; Rouiller I
    Vaccine; 2018 Apr; 36(16):2147-2154. PubMed ID: 29550194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine.
    Xu J; Guo HC; Wei YQ; Dong H; Han SC; Ao D; Sun DH; Wang HM; Cao SZ; Sun SQ
    Appl Microbiol Biotechnol; 2014 Apr; 98(8):3529-38. PubMed ID: 24413974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficient production of porcine circovirus virus-like particles using the nonconventional yeast Kluyveromyces marxianus.
    Duan J; Yang D; Chen L; Yu Y; Zhou J; Lu H
    Appl Microbiol Biotechnol; 2019 Jan; 103(2):833-842. PubMed ID: 30421111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles.
    Li T; Lin H; Zhang Y; Li M; Wang D; Che Y; Zhu Y; Li S; Zhang J; Ge S; Zhao Q; Xia N
    Vaccine; 2014 Apr; 32(17):1921-31. PubMed ID: 24530406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo production of a novel glycoconjugate vaccine against Shigella flexneri 2a in recombinant Escherichia coli: identification of stimulating factors for in vivo glycosylation.
    Kämpf MM; Braun M; Sirena D; Ihssen J; Thöny-Meyer L; Ren Q
    Microb Cell Fact; 2015 Jan; 14():12. PubMed ID: 25612741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. N-glycosylation modification of plant-derived virus-like particles: an application in vaccines.
    Kim HS; Jeon JH; Lee KJ; Ko K
    Biomed Res Int; 2014; 2014():249519. PubMed ID: 24971324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficient application of a baculovirus-silkworm larvae expression system for obtaining porcine circovirus type 2 virus-like particles for a vaccine.
    He Q; Cao Z; Wang P; Lu Q; Zheng H; Sun J
    Arch Virol; 2020 Oct; 165(10):2301-2309. PubMed ID: 32757056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oligosaccharide Antigen Conjugation to Carrier Proteins to Formulate Glycoconjugate Vaccines.
    Smith BR; Guo Z
    Methods Mol Biol; 2021; 2183():305-312. PubMed ID: 32959250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biochemical composition of haemagglutinin-based influenza virus-like particle vaccine produced by transient expression in tobacco plants.
    Le Mauff F; Mercier G; Chan P; Burel C; Vaudry D; Bardor M; Vézina LP; Couture M; Lerouge P; Landry N
    Plant Biotechnol J; 2015 Jun; 13(5):717-25. PubMed ID: 25523794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate.
    Venereo-Sanchez A; Gilbert R; Simoneau M; Caron A; Chahal P; Chen W; Ansorge S; Li X; Henry O; Kamen A
    Vaccine; 2016 Jun; 34(29):3371-80. PubMed ID: 27155499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein.
    Kingston NJ; Kurtovic L; Walsh R; Joe C; Lovrecz G; Locarnini S; Beeson JG; Netter HJ
    Vaccine; 2019 Mar; 37(12):1674-1684. PubMed ID: 30773400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enveloped virus-like particle platforms: vaccines of the future?
    Pitoiset F; Vazquez T; Bellier B
    Expert Rev Vaccines; 2015 Jul; 14(7):913-5. PubMed ID: 25968245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-throughput process development of an alternative platform for the production of virus-like particles in Escherichia coli.
    Ladd Effio C; Baumann P; Weigel C; Vormittag P; Middelberg A; Hubbuch J
    J Biotechnol; 2016 Feb; 219():7-19. PubMed ID: 26707548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rabies virus-like particles expressed in HEK293 cells.
    Fontana D; Kratje R; Etcheverrigaray M; Prieto C
    Vaccine; 2014 May; 32(24):2799-804. PubMed ID: 24631077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of transient expression systems for the rapid production of virus-like particles in plants.
    Thuenemann EC; Lenzi P; Love AJ; Taliansky M; Bécares M; Zuñiga S; Enjuanes L; Zahmanova GG; Minkov IN; Matić S; Noris E; Meyers A; Hattingh A; Rybicki EP; Kiselev OI; Ravin NV; Eldarov MA; Skryabin KG; Lomonossoff GP
    Curr Pharm Des; 2013; 19(31):5564-73. PubMed ID: 23394559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal immunization of pigs with porcine reproductive and respiratory syndrome virus-like particles plus 2', 3'-cGAMP VacciGrade™ adjuvant exacerbates viremia after virus challenge.
    Van Noort A; Nelsen A; Pillatzki AE; Diel DG; Li F; Nelson E; Wang X
    Virol J; 2017 Apr; 14(1):76. PubMed ID: 28403874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preparation and testing of a Haemophilus influenzae Type b/Hepatitis B surface antigen conjugate vaccine.
    An SJ; Woo JS; Chae MH; Kothari S; Carbis R
    Vaccine; 2015 Mar; 33(13):1614-9. PubMed ID: 25659268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.